Skip to main content
SpringerLink
Log in

Use of the Quinolones for the Prophylaxis and Therapy of Infections in Immunocompromised Hosts

  • State-of-The-Art Presentations
  • Published:
Drugs Aims and scope Submit manuscript

Summary

The prevention and treatment of infections are major issues of supportive care in patients with haematological malignancies. Because of their broad antimicrobial activity, the use of fluoro-quinolones for prophylaxis in neutropenic patients has been extensively studied. In comparison with placebo, norfloxacin reduces the incidence of Gram-negative infections, whereas Gram-positive bacterial and fungal infections remain unaffected. Ofloxacin and enoxacin also produce a reduction in fever and documented infections. In randomised studies comparing ciprofloxacin with cotrimoxazole (trimethoprim/sulfamethoxazole) plus colistin (each in combination with nonabsorbable antifungal agents), conflicting results were obtained. The incidence of documented Gram-negative bacterial infections was markedly reduced by ciprofloxacin prophylaxis; however, the number of Gram-positive infections may increase dramatically. Combining ciprofloxacin with a macrolide antibiotic in an attempt to prevent streptococcal infections can result in breakthrough bacteraemias due to resistant Gram-positive pathogens.

Empirical antimicrobial therapy after quinolone prophylaxis should also be directed against microorganisms susceptible to quinolones, since sustained eradication by oral administration cannot be assumed with certainty.

Clinical trials comparing intravenous quinolones in combination with aminoglycosides with widely used standard regimens for the treatment of infections in cancer patients indicate equivalent efficacy; however, in studies of ciprofloxacin alone, response rates were significantly lower compared with standard combinations. Therefore, quinolone monotherapy as empirical treatment in febrile neutropenic patients cannot be recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aoun M, Jacquy C, Debusscher L, Bron D, Lehert M, et al. Peripheral neuropathy associated with fluoroquinolones. Lancet 340: 127, 1992

    Article  PubMed  CAS  Google Scholar 

  • Arcieri GM, Becker N, Esposito B, Griffith E, Heyd A, et al. Safety of intravenous ciprofloxacin. A review. American Journal of Medicine 87 (Suppl. 5A): 92–97, 1989

    Article  Google Scholar 

  • Armstrong D. Protected environments are discomforting and expensive and do not offer meaningful protection. American Journal of Medicine 76: 685–689, 1984

    Article  PubMed  CAS  Google Scholar 

  • Arning M, Wolf HH, Aul C, Heyll A, Scharf RE, et al. Infection prophylaxis in neutropenic patients with acute leukemia — a randomized comparative study with ofloxacin, ciprofloxacin and cotrimoxazole/colistin. Journal of Antimicrobial Chemotherapy 26 (Suppl. D): 137–142, 1990

    PubMed  Google Scholar 

  • Baumgartner JD, Heumann D, Glauser MP. Effects of vaccination of humans with E. coli J5 bacteria on antibodies to core LPS and immunoglobulin levels. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, California, October 23–26, 1988. Abstract no. 200, p. 145, 1988

    Google Scholar 

  • Bayston KF, Want S, Cohen J. A prospective, randomized comparison of ceftazidime and ciprofloxacin as initial empiric therapy in neutropenic patients with fever. American Journal of Medicine 87 (Suppl. 5A): 269–273, 1989

    Article  Google Scholar 

  • Bodey GP. Current status of prophylaxis of infection with protected environments. American Journal of Medicine 76: 678–684, 1984

    Article  PubMed  CAS  Google Scholar 

  • Bodey GP, Rodriguez V. Infections in cancer patients in a protected environment — prophylactic antibiotic program. American Journal of Medicine 59: 497–504, 1975

    Article  PubMed  CAS  Google Scholar 

  • Bodey GP, Rosenbaum B. Effect of prophylactic measures on the microbial flora of patients in protected environment units. Medicine 53: 209–228, 1974

    Article  PubMed  CAS  Google Scholar 

  • Bow EJ, Rayner E, Louie TJ. Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia — the trade-off for reduced gram-negative sepsis. American Journal of Medicine 84: 847–854, 1988

    Article  PubMed  CAS  Google Scholar 

  • Brown AE. Neutropenia, fever, and infection. American Journal of Medicine 76: 421–428, 1984

    Article  PubMed  CAS  Google Scholar 

  • Brown AE, Smith G. Treatment of sepsis in patients with neoplastic diseases with intravenous ciprofloxacin. American Journal of Medicine 87 (Suppl. 5A): 266–268, 1989

    Article  Google Scholar 

  • Brumfitt W, Franklin W, Grady D, Hamilton-Miller JMT, Iliffe A. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrobial Agents and Chemotherapy 26: 757–761, 1984

    Article  PubMed  CAS  Google Scholar 

  • Buckner CD, Clift RA. Prophylaxis and treatment of infection in the immunocompromised host by granulocyte transfusions. Clinics in Haematology 13: 557–572, 1984

    PubMed  CAS  Google Scholar 

  • Chan CC, Oppenheim BA, Anderson H, Swindell R, Scarffe JH. Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients. Antimicrobial Agents and Chemotherapy 33: 87–91, 1989

    Article  PubMed  CAS  Google Scholar 

  • Chang HY, Rodriguez V, Narboni G, Bodey GP, Luna MA, et al. Causes of death in adults with acute leukemia. Medicine 55: 259–268, 1976

    Article  PubMed  CAS  Google Scholar 

  • Cofsky RD, Du Bouchet L, Landesman SH. Recovery of norfloxacin in feces after administration of a single dose to human volunteers. Antimicrobial Agents and Chemotherapy 26: 110–111, 1984

    Article  PubMed  CAS  Google Scholar 

  • Cruciani M, Concia E, Navarra A, Perversi L, Bonetti F, et al. Prophylactic co-trimoxazole versus norfloxacin in neutropenic children — perspective randomized study. Infection 17: 65–69, 1989

    Article  PubMed  CAS  Google Scholar 

  • Dekker AW, Rozenberg-Arska M, Sixma JJ, Verhoef J. Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukemia. Annals of Internal Medicine 95: 555–559, 1981

    PubMed  CAS  Google Scholar 

  • Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Annals of Internal Medicine 106: 7–12, 1987

    PubMed  CAS  Google Scholar 

  • Dietrich M, Gaus W, Vossen J, Van der Waaij D, Wendt F. Protective isolation and antimicrobial decontamination in patients with high susceptibility to infection — a prospective cooperative study of gnotobiotic care in acute leukemia patients. I: clinical results. Infection 5: 107–114, 1977

    CAS  Google Scholar 

  • Donnelly JP, Maschmeyer G, Daenen S. On behalf of the EORTC — Gnotobiotic Project Group. Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukemia — ciprofloxacin versus co-trimoxazole plus colistin. European Journal of Cancer 28A: 873–878, 1992

    Article  PubMed  CAS  Google Scholar 

  • Edlund C, Bergan T, Josefsson K, Solberg R, Nord CE. Effect of norfloxacin on human oropharyngeal and colonic microflora and multiple-dose pharmacokinetics. Scandinavian Journal of Infectious Diseases 19: 113–121, 1987a

    Article  PubMed  CAS  Google Scholar 

  • Edlund C, Lidbeck A, Kager L, Nord CE. Comparative effect of enoxacin and norfloxacin on human colonic microflora. Antimicrobial Agents and Chemotherapy 31: 1846–1848, 1987b

    Article  PubMed  CAS  Google Scholar 

  • Enno A, Darrell J, Hows J, Catovsky D, Goldman JM, et al. Cotrimoxazole for prevention of infection in acute leukaemia. Lancet 2: 395–397, 1978

    Article  PubMed  CAS  Google Scholar 

  • Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. Causes of initial remission induction failure in acute myelogenous leukemia. Blood 60: 309–315, 1982

    PubMed  CAS  Google Scholar 

  • Estey E, Maksymiuk A, Smith T, Fainstein V, Keating M, et al. Infection prophylaxis in acute leukemia. Comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole, and a combination of the two. Archives of Internal Medicine 144: 1562–1568, 1984

    CAS  Google Scholar 

  • Fass RJ, Plouffe JF, Russell JA. Intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections. American Journal of Medicine 87 (Suppl. 5A): 164–168, 1989

    Article  Google Scholar 

  • Fernandes PB. Mode of action, and in vitro and in vivo activities of the fluoroquinolones. Journal of Clinical Pharmacology 28: 156–168, 1988

    PubMed  CAS  Google Scholar 

  • Fischer E, Marano MA, Van Zee KJ, Rock CS, Hawes AS, et al. Interleukin-2 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. Journal of Clinical Investigation 89: 1551–1557, 1992

    Article  PubMed  CAS  Google Scholar 

  • Flaherty JP, Waitley D, Edlin B, George D, Arnow P, et al. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. American Journal of Medicine 87 (Suppl. 5A): 278–282, 1989

    Article  Google Scholar 

  • Gallis HA, Brennan RO, Goodwin SD, Swinney V, Rumbaugh MM, et al. Comparison of the safety and efficacy of intravenous ciprofloxacin and intravenous ceftazidime in the treatment of selected infections. American Journal of Medicine 87 (Suppl. 5A): 176–180, 1989

    Article  Google Scholar 

  • Gonzales MA, Uribe F, Duran Moisen S, Pichardo Fuster A, Selen A, et al. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrobial Agents and Chemotherapy 26: 741–744, 1984

    Article  Google Scholar 

  • Graninger W, Presterl E, Walzl B, Lackner R, Haslinger B, et al. Intravenous ofloxacin in severe infections. Journal of Antimicrobial Chemotherapy 22 (Suppl. D): 123–135, 1990

    Google Scholar 

  • Grünberg RN, Felmingham D, O’Hare MD, Robbins MJ, Perry K, et al. The comparative in-vitro activity of ofloxacin. Journal of Antimicrobial Chemotherapy 22 (Suppl. C): 9–19, 1988

    Google Scholar 

  • Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA). Ciprofloxacin vs norfloxacin as antimicrobial prophylaxis in neutropenic acute leukemia patients: a multicenter randomized comparative study. 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, Texas, September 17–20, 1989. Abstract no. 600, p. 202, 1989

  • Gualtieri RJ, Donowitz GR, Kaiser DL, Hess CE, Sande MA. Double-blind randomized study of prophylactic trimethoprim/ sulfamethoxazole in granulocytopenic patients with hematologic malignancies. American Journal of Medicine 74: 934–940, 1983

    Article  PubMed  CAS  Google Scholar 

  • Gurwith MJ, Brunon JL, Lank BA, Harding GKM, Ronald AR. A prospective controlled investigation of prophylactic trimethoprim/sulfamethoxazole in hospitalized granulocytopenic patients. American Journal of Medicine 66: 248–256, 1979

    Article  PubMed  CAS  Google Scholar 

  • Haddow A, Greene S, Heinz G, Wantuck D. Ciprofloxacin (intravenous/oral) versus ceftazidime in lower respiratory tract infections. American Journal of Medicine 87 (Suppl. 5A): 113–115, 1989

    Article  Google Scholar 

  • Hersh EM, Bodey GP, Nies BA, Freireich EJ. Causes of death in acute leukemia. A ten-year study of 414 patients from 1954–1963, Journal of the American Medical Association 193: 99–103, 1965

    Google Scholar 

  • Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Journal of Infectious Diseases 161: 381–396, 1990

    Article  PubMed  CAS  Google Scholar 

  • Inagaki J, Rodriguez V, Bodey GP. Causes of death in cancer patients. Cancer 33: 568–573, 1974

    Article  PubMed  CAS  Google Scholar 

  • Karp JE, Merz WG, Hendricksen C, Laughon B, Redden T, et al. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. Annals of Internal Medicine 106: 1–7, 1987

    PubMed  CAS  Google Scholar 

  • Kattan J, Droz JP, Ribrag V, Azab M, Boutan-Laroze A, et al. Non-nephrotoxic empiric antimicrobial therapy in febrile neutropenic cancer patients. European Journal of Cancer 28A: 867–870, 1992

    Article  PubMed  CAS  Google Scholar 

  • Kelsey SM, Wood ME, Shaw E, Newland AC. Intravenous ciprofloxacin as empirical treatment of febrile neutropenic patients. American Journal of Medicine 87 (Suppl. 5A): 274–277, 1989

    Article  Google Scholar 

  • Kern W, Kurrle E. Ofloxacin versus trimethoprim-sulfamethoxazole for prevention of infection in patients with acute leukemia and granulocytopenia. Infection 19: 73–80, 1991

    Article  PubMed  CAS  Google Scholar 

  • Khajotia R, Drlicek M, Vetter N. A comparative study of ofloxacin and amoxicillin/clavulanate in hospitalized patients with lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 26 (Suppl. D): 83–91, 1990

    PubMed  Google Scholar 

  • Klastersky J, Debusscher L, Weerts D, Daneau D. Use of oral antibiotics in protected units environment: clinical effectiveness and role in the emergence of antibiotic-resistant strains. Pathologie-Biologie 22: 5–13, 1973

    Google Scholar 

  • Kurrle E, Dekker AW, Gaus W, Haralambie E, Krieger D, et al. Prevention of infection in acute leukemia: a prospective randomized study on the efficacy of two different drug regimens for antimicrobial prophylaxis. Infection 14: 226–232, 1986

    Article  PubMed  CAS  Google Scholar 

  • Lauwers S, Vincken W, Naessens A, Pierard D. Efficacy and safety of pefloxacin in the treatment of severe infections in patients hospitalized in intensive care units. Journal of Antimicrobial Chemotherapy 17 (Suppl. B): 111–115, 1986

    PubMed  Google Scholar 

  • Leigh DA, Walsh B, Harris K, Hancock P, Travers G. Pharmacokinetics of ofloxacin and the effect on the fecal flora of healthy volunteers. Journal of Antimicrobial Chemotherapy 22 (Suppl. C): 115–125, 1988

    PubMed  CAS  Google Scholar 

  • Levine DP, McNeil P, Lerner SA. Randomized, double-blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections. American Journal of Medicine 87 (Suppl. 5A): 160–163, 1989

    Article  Google Scholar 

  • Liang R, Yung R, Chan TK, Chau PY, Lam WK, et al. Ofloxacin versus co-trimoxazole for prevention of infections in neutropenic patients. 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, Texas, September 17–20, 1989. Abstract no. 599, p. 201, 1989

    Google Scholar 

  • Lode H, Wiley R, Höffken G, Wagner J, Borner K. Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections. Antimicrobial Agents and Chemotherapy 31: 1491–1496, 1987

    Article  PubMed  CAS  Google Scholar 

  • Malik IA, Abbas Z, Karim M. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 339: 1092–1096, 1992

    Article  PubMed  CAS  Google Scholar 

  • Maschmeyer G, Haralambie E, Gaus W, Kern W, Dekker AW, et al. Ciprofloxacin and norfloxacin for selective decontamination in patients with severe granulocytopenia. Infection 16: 98–104, 1988

    Article  PubMed  CAS  Google Scholar 

  • Maschmeyer G, Rosenthal E, Wendt F. Bacteriologic surveillance during long-term administration of 4-quinolones. Reviews of Infectious Diseases 11 (Suppl. 5): S1238–S1239, 1989

    Google Scholar 

  • Menon L, Ernst JA, Sy ER, Flores D, Pacia A, et al. Brief report: sequential intravenous/oral ciprofloxacin compared with intravenous ceftazidime in the treatment of serious lower respiratory tract infections. American Journal of Medicine 87 (Suppl. 5A): 119–120, 1989

    Article  Google Scholar 

  • Meunier F, Zinner SH, Gaya H, Calandra T, Viscoli C, et al. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. Antimicrobial Agents and Chemotherapy 35: 873–878, 1991

    Article  PubMed  CAS  Google Scholar 

  • Modai J. The French Multicenter Study Group. Treatment of serious infections with intravenous ciprofloxacin. American Journal of Medicine 87 (Suppl. 5A): 243–247, 1989

    Article  Google Scholar 

  • Mouton Y, Leroy O, Beuscart C, Sivery B, Senneville E, et al. Efficacy of intravenous ofloxacin: a French multicentre trial in 185 patients. Journal of Antimicrobial Chemotherapy 26 (Suppl. D): 115–121, 1990

    PubMed  Google Scholar 

  • Nix DE, Peloquin CA, Cumbo TJ, Sands MF, Schentag JJ. Intravenous ciprofloxacin for nosocomial lower respiratory tract infections. 2nd International Symposium on New Quinolones, Geneva, August 25–27, 1988. Abstract no. 211, p. 211, 1988

    Google Scholar 

  • O’Hanley P, Easaw J, Rugo H, Easaw S. Infectious disease management of adult leukemic patients undergoing chemotherapy: 1982 to 1986 experience at Stanford University hospital. American Journal of Medicine 87: 605–613, 1989

    Article  PubMed  Google Scholar 

  • Paul Ehrlich Society Study Group. Interventional antimicrobial strategy in febrile neutropenic patients with hematological malignancies — results of a three step randomized multicenter study. Clinical Infectious Diseases, in press, 1993

  • Peacock Jr JE, Pegram PS, Weber SF, Leone PA. Prospective, randomized comparison of sequential followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections. American Journal of Medicine 87 (Suppl. 5A): 185–190, 1989

    Article  Google Scholar 

  • Pecquet S, Andremont A, Tancrede C. Effect of oral ofloxacin on fecal bacteria in human volunteers. Antimicrobial Agents and Chemotherapy 31: 124–125, 1987

    Article  PubMed  CAS  Google Scholar 

  • Pizzo PA. The value of protective isolation in preventing nosocomial infections in high risk patients. American Journal of Medicine 70: 631–637, 1981

    Article  PubMed  CAS  Google Scholar 

  • Preisler HD, Goldstein IM, Henderson ES. Gastrointestinal ‘sterilization’ in the treatment of patients with acute leukemia. Cancer 26: 1076–1081, 1970

    Article  PubMed  CAS  Google Scholar 

  • Quintero-Pérez NP, León-Garnica G, Bertin-Montano M, Ortiz-Covarrubias A, Ponce de León A, et al. Prospective, controlled randomized trial of intravenous ciprofloxacin vs ceftazidime in the treatment of serious infections. 2nd International Symposium on New Quinolones, Geneva, August 25–27, 1988. Abstract no. 179, p. 179, 1988

    Google Scholar 

  • Raoof S, Wollschlager C, Khan F. Treatment of respiratory tract infections with ciprofloxacin. Journal of Antimicrobial Chemotherapy 18 (Suppl. D): 139–145, 1986

    PubMed  Google Scholar 

  • Reeves DS. The effect of quinolone antibacterials on the gastrointestinal flora compared with that of other antibacterials. Journal of Antimicrobial Chemotherapy 18 (Suppl. D): 89–102, 1986

    PubMed  CAS  Google Scholar 

  • Regamey C, Steinbach-Lebbin C. Severe infections treated with intravenous ofloxacin: a prospective clinical multicentre Swiss study. Journal of Antimicrobial Chemotherapy 26 (Suppl. D): 107–114, 1990

    PubMed  Google Scholar 

  • Rogers TE. Prevention of infection during neutropenia. British Journal of Haematology 79: 544–549, 1991

    Article  PubMed  CAS  Google Scholar 

  • Rolston KVI, Haron E, Cunningham C, Bodey GP. Intravenous ciprofloxacin for infections in cancer patients. American Journal of Medicine 87 (Suppl. 5A): 261–265, 1989

    Article  Google Scholar 

  • Rozenberg-Arska M, Dekker AW, Verdonck L, Verhoef J. Prevention of bacteremia caused by α-hemolytic streptococci by roxithromycin (RU-28965) in granulocytopenic patients receiving ciprofloxacin. Infection 17: 240–243, 1989

    Article  PubMed  CAS  Google Scholar 

  • Rubin M, Gress J, Marshall D, Kramer B, Steinberg S, et al. Prophylaxis of infectious complications in neutropenic cancer patients with intravenous immunoglobulin. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, California, October 23–26, 1988. Abstract no. 608, p. 215, 1988

    Google Scholar 

  • Schaad UB, Lang AB, Wedgwood J, Ruedeberg A, Que JU, et al. Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis. Lancet 338: 1236–1237, 1991

    Article  PubMed  CAS  Google Scholar 

  • Schaberg D, Terpenning M, Robinson K, Bradley S, Dillon W, et al. Emergence of resistance to ciprofloxacin in enterococci. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 29–October 2, 1991. Abstract no. 982, p. 262, 1991

    Google Scholar 

  • Schimpff SC, Young VM, Greene WH, Vermeulen GD, Moody MR, et al. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Annals of Internal Medicine 77: 707–714, 1972

    CAS  Google Scholar 

  • Schluter G. Ciprofloxacin: toxicologic evaluation of additional safety data. American Journal of Medicine 87 (Suppl. 5A): 37–39, 1989

    Article  Google Scholar 

  • Smith GM, Leyland MJ, Farrell ID, Geddes AM. Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients. Journal of Antimicrobial Chemotherapy 18 (Suppl. D): 165–174, 1986

    PubMed  Google Scholar 

  • Talbot GH, Cassileth PA, Paradiso L, Correa-Coronas R and the Enoxacin Prophylaxis Study Group. Oral enoxacin for infection prevention in acute nonlymphocytic leukemia. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 29 Ȕ October 2, 1991. Abstract no. 1162, p. 292, 1991

    Google Scholar 

  • Teng NNH, Kaplan HS, Hebert JM, Moore C, Douglas H, et al. Protection against gram-negative bacteremia and endotoxinemia with human monoclonal IgM antibodies. Proceedings of the National Academy of Sciences of the United States of America 82: 1790–1794, 1985

    Article  PubMed  CAS  Google Scholar 

  • Trenholme GM, Schmitt BA, Spear J, Gvazdinskas LC, Levin S. Randomized study of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections. American Journal of Medicine 87 (Suppl. 5A): 116–118, 1989

    Article  Google Scholar 

  • Van der Waaij D. Antibiotic choice: the importance of colonisation resistance, pp. 7–31, Research Studies Press, Chichester, 1983

    Google Scholar 

  • Van Saene HKF, Lemmens SEB, Van Saene JJM. Gut decontamination by oral ofloxacin and ciprofloxacin in healthy volunteers. Journal of Antimicrobial Chemotherapy 22 (Suppl. C): 127–134, 1988

    PubMed  Google Scholar 

  • Warren RE, Wimperis JZ, Baglin TP, Constantine CE, Marcus R. Prevention of infection by ciprofloxacin in neutropenia. Journal of Antimicrobial Chemotherapy 26 (Suppl. F): 109–123, 1990

    PubMed  Google Scholar 

  • Winston DJ, Ho WG, Nakao SL, Gale RP, Champlin RE. Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. American Journal of Medicine 80: 884–890, 1986

    Article  PubMed  CAS  Google Scholar 

  • Wollschlager CM, Raoof S, Khan F, Guarneri JJ, Labombardi V, et al. Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections. American Journal of Medicine 82 (Suppl. 4A): 164–168, 1987

    PubMed  CAS  Google Scholar 

  • Wood ME, Newland AC. Intravenous ciprofloxacin in the treatment of infection in immunocompromised patients. Journal of Antimicrobial Chemotherapy 18 (Suppl. D): 175–178, 1986

    PubMed  Google Scholar 

  • Wright DG. Granulocyte transfusions: thinking twice. American Journal of Medicine 76: 637–644, 1984

    Article  PubMed  CAS  Google Scholar 

  • Yates JW, Holland JF. A controlled study of isolation and endogenous microbial suppression in acute myelocytic leukemia patients. Cancer 32: 1490–1498, 1973

    Article  PubMed  CAS  Google Scholar 

  • Young LS. The role of granulocyte transfusions in treating and preventing infection. Cancer Treatment Reports 67: 109–111, 1983

    PubMed  CAS  Google Scholar 

  • Zanetti G, Glauser MP, Baumgartner JD. Use of immunoglobulins in prevention and treatment of infection in critically ill patients: review and critique. Review of Infectious Diseases 13: 15–22, 1991

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Haematology and Oncology, Ev. Krankenhaus Essen-Werden, Pattbergstr. 1-3, D-4300, Essen 16, Germany

    Georg Maschmeyer

Authors
  1. Georg Maschmeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maschmeyer, G. Use of the Quinolones for the Prophylaxis and Therapy of Infections in Immunocompromised Hosts. Drugs 45 (Suppl 3), 73–80 (1993). https://doi.org/10.2165/00003495-199300453-00014

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199300453-00014

Keywords

Search

Navigation